Cory Perugino is a Rheumatology/Immunology physician affiliated with Harvard University. OpenAlex indexes 81 publications with 6,123 citations (h-index 31).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Yawkey 2c
Boston, MA 021142621
Telephone
617-726-7938Registry record last updated 10 Feb 2016.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20256 payments
- Amgen Inc.Program year20248 payments
- Merck Sharp & Dohme LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40.9%Folate Analog Metabolic Inhibitor13.3%Methotrexate100%Part D<11 patientsJAK inhibitor12%Xeljanz Xr100%Part D<11 patients+ 2 more classes in this area
Nervous system
21.3%SNRI15.1%Duloxetine Hcl100%Part D<11 patientsCholinergic Receptor Agonist6.2%Cevimeline Hcl100%Part D<11 patientsMetabolism & gastrointestinal
20%Corticosteroid14.7%Prednisone100%Part D≥15 patientsH2 blocker5.3%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Defining the antigenic determinants of the adaptive immune response in IgG4-related disease
Massachusetts General Hospital
FY2025$174,960K08AR079615 - Defining the antigenic determinants of the adaptive immune response in IgG4-related disease
Massachusetts General Hospital
FY2024$174,960K08AR079615 - Defining the antigenic determinants of the adaptive immune response in IgG4-related disease
Massachusetts General Hospital
FY2023$174,960K08AR079615
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiorgan involvement and circulating IgG1 predict hypocomplementaemia in IgG4-related disease
Annals of the Rheumatic Diseases
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”